Study Title: Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
 

• • Status: Terminated
  • Participating Sites:
    • University of Michigan Rogel Cancer Center
    • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
    • University of Wisconsin Carbone Cancer Center
  • Learn more:
    • clinicaltrials.gov: NCT03927105
    • Big Ten CRC News Release

Study Contact: studies@hoosiercancer.org; (317) 921-2050.